Automated quantification of MART1-verified Ki-67 indices: useful diagnostic aid in melanocytic lesions.

The MART1-verified Ki-67 proliferation index is a valuable aid to distinguish melanomas from nevi. Because such indices are quantifiable by image analysis, they may provide a novel automated diagnostic aid. This study aimed to validate the diagnostic performance of automated dermal Ki-67 indices and to explore the diagnostic capability of epidermal Ki-67 in lesions both with and without a dermal component. In addition, we investigated the automated indices' ability to predict sentinel lymph node (SLN) status. Paraffin-embedded tissues from 84 primary cutaneous melanomas (35 with SLN biopsy), 22 melanoma in situ, and 270 nevi were included consecutively. Whole slide images were captured from Ki-67/MART1 double stains, and image analysis computed Ki-67 indices for epidermis and dermis. In lesions with a dermal component, the area under the receiver operating characteristic (ROC) curve was 0.79 (95% confidence interval [CI], 0.72-0.86) for dermal indices. By excluding lesions with few melanocytic cells, this area increased to 0.93 (95% CI, 0.88-0.98). A simultaneous analysis of epidermis and dermis yielded an ROC area of 0.94 (95% CI, 0.91-0.96) for lesions with a dermal component and 0.98 (95% CI, 0.97-1.0) for lesions with a considerable dermal component. For all lesions, the ROC area of the simultaneous analysis was 0.89 (95% CI, 0.85-0.92). SLN-positive patients generally had a higher index than SLN-negative patients (P ≤ .003). Conclusively, an automated diagnostic aid seems feasible in melanocytic pathology. The dermal Ki-67 index was inferior to a combined epidermal and dermal index in diagnosis but valuable for predicting the SLN status of our melanoma patients.

[1]  M. Kornstein,et al.  The medicolegal aspect of error in pathology: a search of jury verdicts and settlements. , 2009, Archives of pathology & laboratory medicine.

[2]  P. Heenan Histological Diagnosis of Nevi and Melanoma , 2005 .

[3]  A. Patereli,et al.  Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi. , 2007, Journal of the American Academy of Dermatology.

[4]  Bonnie L. Balzer,et al.  Nevic Mitoses: A Review of 1041 Cases , 2013, The American Journal of dermatopathology.

[5]  P. G. Lang,et al.  Sentinel-Node Biopsy or Nodal Observation in Melanoma , 2007 .

[6]  Patricia Switten Nielsen,et al.  Immunohistochemical Double Stains Against Ki67/MART1 and HMB45/MITF: Promising Diagnostic Tools in Melanocytic Lesions , 2011, The American Journal of dermatopathology.

[7]  L. Akslen,et al.  Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma , 2010, BMC Cancer.

[8]  T. Brenn,et al.  Pitfalls in the evaluation of melanocytic lesions , 2012, Histopathology.

[9]  J. Kril,et al.  A Zonal Comparison of MIB1-Ki67 Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2000, The American Journal of dermatopathology.

[10]  R. Bergman,et al.  MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. , 2001, Journal of the American Academy of Dermatology.

[11]  M. Bracken,et al.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. , 2009, Journal of the National Cancer Institute.

[12]  H. Shaw,et al.  Should Tumor Mitotic Rate and Patient Age, As Well As Tumor Thickness, be Used to Select Melanoma Patients for Sentinel Node Biopsy? , 2004, Annals of Surgical Oncology.

[13]  J. Grichnik,et al.  Accurate identification of proliferative index in melanocytic neoplasms with Melan‐A/Ki‐67 double stain , 2010, Journal of cutaneous pathology.

[14]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Nasr,et al.  Comparison of pHH3, Ki-67, and Survivin Immunoreactivity in Benign and Malignant Melanocytic Lesions , 2008, The American Journal of dermatopathology.

[16]  R. Parwaresch,et al.  Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. , 1997, Journal of the American Academy of Dermatology.

[17]  H. Schmidt,et al.  Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma , 2013, Modern Pathology.

[18]  Patricia Switten Nielsen,et al.  Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions. , 2012, Archives of pathology & laboratory medicine.

[19]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[20]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Soyer Ki 67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters. , 1991, Journal of cutaneous pathology.

[22]  R. Scolyer,et al.  Melanocytic lesions of the face: diagnostic pitfalls. , 2004, Annals of the Academy of Medicine, Singapore.

[23]  Jakob Raundahl,et al.  Practical considerations of image analysis and quantification of signal transduction IHC staining. , 2011, Methods in molecular biology.

[24]  B. Lebe,et al.  The Significance of Ki-67 Proliferative Index and Cyclin D1 Expression of Dysplastic Nevi in the Biologic Spectrum of Melanocytic Lesions , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[25]  H. Kutzner,et al.  Frequent Mitotic Activity in Banal Melanocytic Nevi Uncovered by Immunohistochemical Analysis , 2010, The American Journal of dermatopathology.

[26]  M. Kallioinen,et al.  A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. , 2011, Human pathology.

[27]  M. Selim,et al.  Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis , 2005, Modern Pathology.

[28]  D. Ivan,et al.  Use of immunohistochemistry in the diagnosis of melanocytic lesions: applications and pitfalls. , 2010, Future oncology.

[29]  R. Reed,et al.  Ki-67 and p53 Expression in Minimal Deviation Melanomas as Compared with Other Nevomelanocytic Lesions , 2003, Modern Pathology.

[30]  Two-graph Receiver Operating Characteristic , 2002 .

[31]  P. Leboit Pathology and genetics of skin tumours , 2006 .

[32]  D. Elder,et al.  Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Hasegawa Histological grading and MIB‐1 labeling index of soft‐tissue sarcomas , 2007, Pathology international.